Target intelligence / Profile preview

Splicing factor U2AF 35 kDa subunit (U2AF1)

Target
U2AF1
Molecular classification
Splicing factor, RNA-binding protein, Component of spliceosome, Non-snRNP protein
01

Overview

U2AF1 is a splicing factor of 35 kDa that serves as the small subunit of the U2 auxiliary factor complex. It is essential for the recognition of the AG dinucleotide at the 3’ splice site during spliceosome assembly in pre-mRNA processing. Mutations in U2AF1, including the Q157R substitution, are recurrent in multiple hematologic malignancies and solid tumors, and have been shown to alter normal splicing patterns, contributing to oncogenesis and disease progression. The U2AF1 protein acts primarily through RNA-protein and protein-protein interactions that facilitate gene expression regulation. U2AF1 is a promising but challenging therapeutic target due to its ubiquitous role in normal cell physiology[1][3][9].

Other names
U2 small nuclear RNA auxiliary factor 1Splicing factor U2AF 35 kDa subunitU2AF1
02

Mechanism of action

Drugs targeting spliceosome machinery can act by modulating splicing efficiency or correcting aberrant splicing induced by U2AF1 mutations.

03

Biological functions

RNA splicing (pre-mRNA splicing)Recognition of 3' splice site AG dinucleotideAssembly of spliceosomeRegulation of gene expressionMaintenance of hematopoietic stem cells
04

Disease associations

CancerMyelodysplastic syndrome (MDS)Acute myeloid leukemia (AML)Chronic myelomonocytic leukemiaPrimary myelofibrosisLung carcinomaPancreatic carcinomaOvarian carcinoma
05

Safety considerations

Off-target effects due to the central role of splicing in all cellsLoss of normal hematopoietic stem cell functionPotential for genotoxicity and abnormal gene expression
06

Interacting drugs

As of now, no FDA-approved drugs directly and specifically target U2AF1, but clinical trials are investigating splicing modulators and other agents targeting spliceosome machinery in cancers harboring U2AF1 mutations
07

Biomarkers

U2AF1 mutation status (Q157R and S34F most common) is used as a biomarker for cancer pathogenesis, prognosis, and potential therapeutic response, especially in MDS and AML

Beyond the preview

Go deeper on Splicing factor U2AF 35 kDa subunit (U2AF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Splicing factor U2AF 35 kDa subunit (U2AF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call